{"ticker": {"uuid": "7aff9322-9703-45ff-a94a-ed4b53954a81", "symbol": "3681", "name": "SinoMab BioScience Limited", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxQSnlqLW50RXFXcmk1ekhya1BQMVdfS0hMUFNaNHJ3RWxtQmZOWlFDWC1PMzJ3YVNEYmtTUU1tR2U0OGgwSXhwYnZxM3RtMXdvU1dZbVU1b3Exb0I5eDVtYnU5RFJmeXpIZkxOQmtYNEU2SFNZa0ZyZGtPSzJnQ21mS2hnYmc4THJWZVBqdlRIQ2tFYVdfUnZ3LThUdXozLVFpcWhkd1FrNlFmN0EtRHU1RTNYbXVyZG5XZzNuRDk5T3RxMzhpcmk3ZURPOGMyNGtCYnFlOGIyenVhV1lLcjZ1S2g2UEtIZWxwOTl2VS1uUlZsbVMwalRqUW1aVE4zVmhUTXVIN1hiOTBPRnhiRHZmWTdQMTY0UlU5UzBoTWlVMjQ0SE9uYjBUbklsWmxLak9PVDIw?oc=5", "source_name": "Media OutReach Newswire", "published_at": "2023-04-27T07:00:00+00:00", "published_display": "27 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxOaHMtV3hwM3J5S3lONjdYcVRUSktvT3o2MHAtd3lJY0xodDEyVnE3MDVOM3hJamNxQXhVRGI3RHdrclVhNUxPZ3VaUXA4V3p0Q1hYQVB4YkRKa0I0bzdsTTFXR0tTMVpSTTYtRjhUV2xSRXNnLWFpUnZXVjJJSDU3ZXkzc0pENXFqd291ODJJcEh1SnBFLXAxUmxmWUNvNnhpMmwtMEZIRXA3TzhVOVdmQnFaV3V4N2p5SGtpSXQyWTZaNVROSThBM3Z6RE1ERmNhNkZiTWNOdlE1ZHR5bjdzNkRLN2c1UFdMRDVsNzdnT25Hak94ckdYQm9aMnlJVTMwXzVKT05SWkUwWEltcEM3eFNQUWFFNUVkbXlxZV9GVm1EblRYYjVidzVZTnNQUW8?oc=5", "source_name": "ACN Newswire", "published_at": "2022-06-21T07:00:00+00:00", "published_display": "21 Jun 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm SinoMab says Hong Kong well placed to lead regional industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2019-11-12T08:00:00+00:00", "published_display": "12 Nov 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxQSnlqLW50RXFXcmk1ekhya1BQMVdfS0hMUFNaNHJ3RWxtQmZOWlFDWC1PMzJ3YVNEYmtTUU1tR2U0OGgwSXhwYnZxM3RtMXdvU1dZbVU1b3Exb0I5eDVtYnU5RFJmeXpIZkxOQmtYNEU2SFNZa0ZyZGtPSzJnQ21mS2hnYmc4THJWZVBqdlRIQ2tFYVdfUnZ3LThUdXozLVFpcWhkd1FrNlFmN0EtRHU1RTNYbXVyZG5XZzNuRDk5T3RxMzhpcmk3ZURPOGMyNGtCYnFlOGIyenVhV1lLcjZ1S2g2UEtIZWxwOTl2VS1uUlZsbVMwalRqUW1aVE4zVmhUTXVIN1hiOTBPRnhiRHZmWTdQMTY0UlU5UzBoTWlVMjQ0SE9uYjBUbklsWmxLak9PVDIw?oc=5", "source_name": "Media OutReach Newswire", "published_at": "2023-04-27T07:00:00+00:00", "published_display": "27 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxOaHMtV3hwM3J5S3lONjdYcVRUSktvT3o2MHAtd3lJY0xodDEyVnE3MDVOM3hJamNxQXhVRGI3RHdrclVhNUxPZ3VaUXA4V3p0Q1hYQVB4YkRKa0I0bzdsTTFXR0tTMVpSTTYtRjhUV2xSRXNnLWFpUnZXVjJJSDU3ZXkzc0pENXFqd291ODJJcEh1SnBFLXAxUmxmWUNvNnhpMmwtMEZIRXA3TzhVOVdmQnFaV3V4N2p5SGtpSXQyWTZaNVROSThBM3Z6RE1ERmNhNkZiTWNOdlE1ZHR5bjdzNkRLN2c1UFdMRDVsNzdnT25Hak94ckdYQm9aMnlJVTMwXzVKT05SWkUwWEltcEM3eFNQUWFFNUVkbXlxZV9GVm1EblRYYjVidzVZTnNQUW8?oc=5", "source_name": "ACN Newswire", "published_at": "2022-06-21T07:00:00+00:00", "published_display": "21 Jun 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm SinoMab says Hong Kong well placed to lead regional industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2019-11-12T08:00:00+00:00", "published_display": "12 Nov 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1.19, "latest_week": "2026-07-10", "one_week_move": -8.5, "four_week_move": -7.8, "twelve_week_move": -24.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.953069, "market_dynamics_buy_signal": false, "relative_strength": -28.439768, "fair_value_gap": -22.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.8909, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.5% over one week, -7.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Media OutReach Newswire", "count": 1}, {"label": "ACN Newswire", "count": 1}, {"label": "South China Morning Post", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.5% over one week, -7.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis"}], "updated_at": "2026-07-18T02:04:30.643790+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}